Block Listing 6 Monthly Return
Shield Therapeutics plc has provided a six-monthly update on its block listing returns for various share schemes covering the period from January 1, 2026, to June 30, 2026. The Shield Therapeutics Retention Share Plan has a remaining balance of 39,794 unallotted securities, while the Shield Therapeutics plc 2016 Company Share Option Plan has 341,020 unallotted securities. The Shield Therapeutics plc 2016 Long Term Incentive Plan has 24,273 unallotted securities. Notably, the Shield Therapeutics Retention and Performance Share Plan saw 2,023,801 securities issued during the period, reducing its balance of unallotted securities to 9,697,164 from an initial 11,720,965. No increases were applied to any of the block schemes during this reporting period.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
|---|---|---|---|---|
| Name of scheme: | Shield Therapeutics Retention Share Plan | |||
| Period of return: | From: | 01 January 2026 | To: | 30 June 2026 |
| Balance of unallotted securities under scheme(s) from previous return: | 39,794 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 39,794 | |||
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | Shield Therapeutics plc 2016 Company Share Option Plan | |||
| Period of return: | From: | 01 January 2026 | To: | 30 June 2026 |
| Balance of unallotted securities under scheme(s) from previous return: | 341,020 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 341,020 | |||
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | The Shield Therapeutics plc 2016 Long Term Incentive Plan | |||
| Period of return: | From: | 01 January 2026 | To: | 30 June 2026 |
| Balance of unallotted securities under scheme(s) from previous return: | 24,273 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 24,273 | |||
| Name of applicant: | SHIELD THERAPEUTICS PLC | |||
| Name of scheme: | Shield Therapeutics Retention and Performance Share Plan | |||
| Period of return: | From: | 01 January 2026 | To: | 30 June 2026 |
| Balance of unallotted securities under scheme(s) from previous return: | 11,720,965 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 2,023,801 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 9,697,164 | |||
| Name of contact: | Lucy Huntington-Bailey | |||
| Telephone number of contact: | +44 (0) 191 511 8500 |
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.